ImmuCell Historical Income Statement
| ICCC Stock | USD 4.12 0.40 10.75% |
Historical analysis of ImmuCell income statement accounts such as Total Revenue of 18.3 M or Gross Profit of 3.9 M can show how well ImmuCell performed in making a profits. Evaluating ImmuCell income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of ImmuCell's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining ImmuCell latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ImmuCell is a good buy for the upcoming year.
ImmuCell |
About ImmuCell Income Statement Analysis
ImmuCell Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to ImmuCell shareholders. The income statement also shows ImmuCell investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
ImmuCell Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts ImmuCell generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of ImmuCell minus its cost of goods sold. It is profit before ImmuCell operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Operating Income
Operating Income is the amount of profit realized from ImmuCell operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of ImmuCell is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Cost Of Revenue
Cost of Revenue is found on ImmuCell income statement and represents the costs associated with goods and services ImmuCell provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from ImmuCell's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into ImmuCell current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuCell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.At present, ImmuCell's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 18.3 M, whereas Gross Profit is forecasted to decline to about 3.9 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 8.7M | 7.6M | 4.4M | 3.9M | Total Revenue | 19.2M | 18.6M | 17.5M | 18.3M |
ImmuCell income statement Correlations
Click cells to compare fundamentals
ImmuCell Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ImmuCell income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 2.3M | 2.3M | 2.5M | 2.5M | 2.7M | 2.9M | |
| Interest Expense | 431.8K | 412.7K | 314.4K | 340.9K | 402.4K | 422.5K | |
| Total Revenue | 13.7M | 15.3M | 19.2M | 18.6M | 17.5M | 18.3M | |
| Gross Profit | 6.7M | 6.9M | 8.7M | 7.6M | 4.4M | 3.9M | |
| Other Operating Expenses | 14.7M | 16.7M | 19.0M | 20.9M | 23.2M | 24.4M | |
| Operating Income | (954K) | (1.4M) | (2.2M) | (2.3M) | (5.7M) | (5.5M) | |
| Ebit | (954K) | (1.4M) | 245.2K | (2.3M) | (5.2M) | (5.0M) | |
| Ebitda | 1.3M | 967.3K | 2.7M | 188.6K | (2.5M) | (2.4M) | |
| Cost Of Revenue | 7.0M | 8.5M | 10.6M | 10.9M | 13.1M | 13.7M | |
| Total Operating Expenses | 7.7M | 8.2M | 8.4M | 9.9M | 9.6M | 10.1M | |
| Net Income | (1.3M) | (1.0M) | (78K) | (2.5M) | (5.8M) | (5.5M) | |
| Income Tax Expense | 28K | (10K) | 9K | 8K | 4.6K | 4.4K | |
| Research Development | 3.7M | 4.4M | 4.2M | 4.5M | 4.4M | 4.6M | |
| Income Before Tax | (1.3M) | (1.0M) | (69K) | (2.5M) | (5.8M) | (5.5M) | |
| Total Other Income Expense Net | (314K) | 348K | (326.5K) | (187K) | (21.9K) | (20.8K) | |
| Selling General Administrative | 1.7M | 1.7M | 1.7M | 2.3M | 2.1M | 1.5M | |
| Net Income Applicable To Common Shares | (1.3M) | (1.0M) | (78K) | (2.5B) | (2.2B) | (2.1B) | |
| Selling And Marketing Expenses | 4.0M | 3.9M | 4.2M | 5.5M | 3.1M | 2.4M | |
| Net Income From Continuing Ops | (1.3M) | (1.0M) | (78K) | (2.5M) | (6.3M) | (6.0M) | |
| Non Operating Income Net Other | (195.6K) | (413.5K) | (313.5K) | 348.1K | 313.3K | 329.0K | |
| Tax Provision | 28.2K | (10K) | 9K | 8K | 4.8K | 4.5K | |
| Interest Income | 118.3K | 27.4K | 18.8K | 153.1K | 143.9K | 74.4K | |
| Net Interest Income | (313.5K) | (385.2K) | (295.5K) | (195.4K) | (273.0K) | (286.6K) | |
| Reconciled Depreciation | 2.3M | 2.3M | 2.5M | 2.5M | 2.6M | 2.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ImmuCell offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ImmuCell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immucell Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immucell Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuCell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.63) | Earnings Share (0.49) | Revenue Per Share 2.991 | Quarterly Revenue Growth 0.549 | Return On Assets (0.05) |
The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.